StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a report published on Sunday. The firm issued a sell rating on the biotechnology company’s stock.
Evogene Trading Down 2.1 %
Evogene stock opened at $1.90 on Friday. The firm has a market cap of $10.19 million, a PE ratio of -0.43 and a beta of 1.30. Evogene has a 12 month low of $1.20 and a 12 month high of $10.40. The stock’s 50 day simple moving average is $1.70 and its two-hundred day simple moving average is $3.26.
Institutional Trading of Evogene
An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
See Also
- Five stocks we like better than Evogene
- How Technical Indicators Can Help You Find Oversold Stocks
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- Which Wall Street Analysts are the Most Accurate?
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- Energy and Oil Stocks Explained
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
